drugset
drugset / Trial / NCT02780427

ED50 and ED95 of Intranasal Dexmedetomidine in Pediatric Patients Undergoing Transthoracic Echocardiography Study

NCT02780427 ↗

Phase 4 Completed 320 enrolled Guangzhou Women and Children's Medical Center
RandomizedParallel-groupTriple-blindPrevention

Summary

The median effective dose (ED50) and ED95 of intranasal dexmedetomidine as a single bolus have not been described for sedation in children undergoing transthoracic echocardiography (TEE) study. This information is important to compare agents and to determine the most effective sedative dose. The investigators performed a two-stage study to determine the ED50 and the ED95 of intranasal dexmedetomidine to investigate age-related differences in participants undergoing transthoracic echocardiography study.

Timeline

Start
2019-08-10
Primary completion
2021-01-01
Completion
2022-05-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 2.5 ug/kg Intranasal

Indications

No indication recorded.